查看购物车
  • Traditional Chinese
  • English
  • Japanese
封面
市场调查报告书
商品编码
1832114

血友病市场规模、份额、趋势及预测（按类型、治疗、疗法和地区划分），2025 年至 2033 年

Hemophilia Market Size, Share, Trends and Forecast by Type, Treatment, Therapy, and Region, 2025-2033
出版日期: | 出版商: IMARC | 英文 137 Pages | 商品交期: 2-3个工作天内

价格

2024年，全球血友病市场规模达143.3亿美元。展望未来， IMARC Group预测，到2033年，该市场规模将达到334.2亿美元，2025-2033年期间的复合年增长率为9.37%。目前，北美占据市场主导地位，2024年其市占率将超过49.7%。由于对创新疗法（包括基因疗法和延长半衰期的疗法）的投资增加，市场正在不断扩张。同时，患者意识的提升和个人化医疗的进步持续推动市场发展，进一步支持了已开发地区和新兴地区的血友病市场份额。

由于高额的研发投入，血友病市场发生了翻天覆地的变化。这些资金推动了基因疗法等疗法的创新，旨在为血友病患者提供持久的治疗方案。随着全球血友病病例的增加，人们努力改进治疗方法，试图降低因子替代疗法的比率。事实上，延长半衰期疗法就是这样一种治疗方法，它降低了患者的输液率，从而提高了他们的生活品质。另一方面，个人化治疗方法正在不断发展，人们越来越倾向于个人化医疗，以确保治疗更符合个别患者的特定需求。在美国，对晚期血友病治疗的需求已经大幅增长，这主要是由于人们对更好、更简单的治疗方法的需求。

随着血友病患者数量的增加，人们越来越关注那些能够提高疗效、减少输液次数、最终改善患者生活品质的疗法。基因疗法有望提供长期或永久性的治疗方案，并已引起广泛关注，目前美国已有多项临床试验正在进行中。美国政府和医疗机构也对开放这些新疗法的管道表现出更大的兴趣，致力于推动这些疗法的普及和价格的合理化。鑑于患者正在寻求替代传统凝血因子替代疗法（这些疗法需要定期输液）的方案，这一点尤其重要。此外，新型凝血因子浓缩物和非凝血因子疗法的核准为患者提供了更好的治疗选择，减少了出血事件的发生，并降低了就诊需求。

血友病市场趋势：

血友病病例增加和进展

全球血友病和遗传性疾病发生率的上升是推动全球血友病市场成长的关键驱动力。 2023年，全球近219,000人被诊断出患有血友病。诊断数量的增加，加上预防性治疗的日益普及，代表着巨大的市场成长机会。此外，各政府机构正在进行宣传活动，以提高人们对早期诊断和新生儿筛检重要性的认识，这为该行业带来了积极的成长前景。此外，有限的治疗方案也推动了研发 (R&D) 投资的增加。该领域的领先公司正专注于开发先进的诊断工具和疗法，旨在提高治疗的有效性和准确性，从而提升市场潜力。此外，全球范围内对建立专门血友病治疗中心 (HTC) 的大量投资预计将进一步推动市场成长。例如，2023年，HTC 资助计画为12个国家的20个中心提供了支持，加强了资料收集并改善了病患照护。

血友病基因治疗的进展

随着创新疗法的涌现，全球血友病市场正在经历重大变革，以应对长期存在的治疗挑战。传统疗法，例如频繁的因子替代输注，通常成本高昂，且患者依从性差。这导致对替代疗法的需求日益增长，这些疗法不仅能改善患者的预后，还能提供长期解决方案。基因疗法的兴起是最具前景的进展之一，它有可能消除定期输注的需要，并为全球血友病患者提供更永续的治疗模式。例如，2024年12月，印度首例利用慢病毒载体成功进行的重症血友病A的人体基因治疗。这项突破性的治疗实现了零出血事件，证明了其在长期预防出血方面的有效性。该疗法还消除了重复输注的需要，从而降低了患者的成本和负担。这项成功凸显了基因疗法在血友病市场的未来潜力，使其成为改变治疗格局的有力竞争者。随着基因疗法的蓬勃发展，预计其市场规模将大幅扩张，为全球血友病患者提供创新、经济高效且长期有效的解决方案。随着这一转变，血友病市场趋势将与市场对先进、永续治疗方案日益增长的需求保持一致。

血友病治疗的便利性与个人化

随着全球血友病市场持续成长，人们越来越重视提供更大便利性和个人化的治疗。许多目前的疗法，尤其是静脉输液，非常耗时，需要频繁就医，并且可能给患者带来不便。随着以患者为中心的照护变得越来越重要，对透过简单给药和个人化治疗方案来改善生活品质的疗法的需求正在上升。这刺激了更易于获取和对患者友好的治疗方案的开发，进一步推动了血友病市场的创新。例如，2025 年 1 月，FDA 批准了 Concizumab-mtci (Alhemo)，这是第一个针对具有抑制剂的血友病 A 和 B 的皮下预防性治疗。这种基于 3 期临床试验资料的新型治疗方法透过提供皮下注射为患者提供了更便捷的选择，无需静脉输液。 Alhemo 的核准对存在抑制剂的患者来说意义非凡，它为现有疗法提供了急需的替代方案，并提升了血友病管理的灵活性和便利性。随着这项新获批，血友病市场正朝着不仅更有效，而且能够根据患者个体需求量身定制的疗法转变，使治疗更加便捷。因此，该市场正在快速扩张，为满足全球血友病患者多样化需求的个人化护理解决方案提供了更多机会。

目录

第一章：前言

第二章：范围与方法

  • 研究目标
  • 利害关係人
  • 资料来源
    • 主要来源
    • 二手资料
  • 市场评估
    • 自下而上的方法
    • 自上而下的方法
  • 预测方法

第三章：执行摘要

第四章：简介

第五章：全球血友病市场

  • 市场概况
  • 市场表现
  • COVID-19的影响
  • 市场预测

第六章：市场细分：依类型

  • 血友病A
  • 血友病B
  • 血友病C
  • 其他的

第七章：市场区隔：依治疗方式

  • 一经请求
  • 预防

第八章：市场区隔：依疗法

  • 替代疗法
  • ITI 治疗
  • 基因治疗

第九章：市场细分：依地区

  • 北美洲
    • 美国
    • 加拿大
  • 亚太
    • 中国
    • 日本
    • 印度
    • 韩国
    • 澳洲
    • 印尼
    • 其他的
  • 欧洲
    • 德国
    • 法国
    • 英国
    • 义大利
    • 西班牙
    • 俄罗斯
    • 其他的
  • 拉丁美洲
    • 巴西
    • 墨西哥
    • 其他的
  • 中东和非洲

第 10 章：SWOT 分析

第 11 章：价值链分析

第 12 章：波特五力分析

第十三章：价格分析

第 14 章：竞争格局

  • 市场结构
  • 关键参与者
  • 关键参与者简介
    • Baxter International Inc.
    • Bayer AG
    • BioMarin Pharmaceutical Inc.
    • CSL Behring (CSL Limited)
    • F. Hoffmann-La Roche AG
    • Grifols SA
    • Kedrion SpA
    • Novo Nordisk A/S
    • Octapharma AG
    • Pfizer Inc.
    • Sanofi SA
    • Takeda Pharmaceutical Company Limited
Product Code: SR112025A4508

The global hemophilia market size was valued at USD 14.33 Billion in 2024. Looking forward, IMARC Group estimates the market to reach USD 33.42 Billion by 2033, exhibiting a CAGR of 9.37% during 2025-2033. North America currently dominates the market, holding a significant market share of over 49.7% in 2024.The market is expanding due to increased investment in innovative therapies, including gene therapy and treatments with extended half-lives. At the same time, rising patient awareness and advancements in personalized medicine continue to drive the market, further supporting the hemophilia market share in both developed and emerging regions.

The market has undergone tremendous evolution on account of being subject to high R&D spending. The funding bestowed innovations in therapies such as gene therapies which purport to give solutions that would last such patients. Efforts have gone into enhancing treatments in an attempt to cut down factor replacement therapy rate as hemophilia cases are on the rise globally. With longer half-life treatment being one such treatment, in fact, it decreases the infusion rate for the patients to elevate their quality of life. Another aspect has been the personalized treatment methods that have been under development with growing inclination toward personalized medicine, ensuring that treatment cater more toward the particular needs of an individual patient. In the U.S., demand for advanced hemophilia treatment has picked up well, driven largely by the demand for better and easy methods of treatments.

As the population of individuals with hemophilia increases, there is a rising focus on therapies that offer improved efficacy and fewer infusions, ultimately enhancing patients' quality of life. Gene therapies, which offer the potential for long-term or permanent treatment solutions, have garnered significant attention, with several clinical trials underway in the country. The US government and healthcare centers have also expressed greater interest in opening up access to these new treatments, promoting treatments to become more accessible and affordable. This has been particularly significant as patients look for alternatives to conventional factor replacement treatments that take place regularly through infusions. Additionally, the approval of new clotting factor concentrates, and non-factor therapies has provided better management options for patients, allowing for fewer bleeding episodes and reducing the need for hospital visits.

Hemophilia Market Trends:

Increasing Hemophilia Cases and Advancements

The increasing worldwide incidence of hemophilia and genetic disorders are key drivers fuelling the global hemophilia market growth. In 2023, almost 219,000 individuals globally were diagnosed with hemophilia. The increasing number of diagnoses, combined with the growing adoption of prophylactic therapy, represents a huge opportunity for market growth. Additionally, various governmental bodies are conducting campaigns to raise awareness about the importance of early diagnosis and neonatal screening, which is fostering positive growth prospects for the industry. Furthermore, increased investment in research and development (R&D) is being driven by the limited treatment options available. Leading companies in the sector are focusing on developing advanced diagnostic tools and therapies that aim to improve treatment effectiveness and precision, boosting the market's potential. Moreover, substantial investments in the creation of specialized hemophilia treatment centers (HTCs) worldwide are expected to drive market growth further. For example, in 2023, the HTC Funding Program provided support to 20 centers across 12 countries, strengthening data collection and enhancing patient care.

Advancements in Gene Therapy for Hemophilia

The global hemophilia market is undergoing significant transformation as new and innovative therapies emerge to address longstanding challenges in treatment. Traditional approaches, such as frequent factor replacement infusions, often come with high costs and compliance issues for patients. This has led to an increasing demand for alternative therapies that not only improve patient outcomes but also provide long-term solutions. One of the most promising advancements is the rise of gene therapy, offering the potential to eliminate the need for regular infusions and provide a more sustainable treatment model for hemophilia patients worldwide. For instance, in December 2024, India's first human gene therapy for severe Hemophilia A was successfully conducted using a lentiviral vector. This groundbreaking treatment resulted in zero bleeding episodes, demonstrating its effectiveness in providing long-term protection against bleeding. The therapy also eliminated the need for repeated infusions, reducing both the cost and burden on patients. This success highlights the future potential of gene therapies in the hemophilia market, making them a strong contender in transforming the treatment landscape. As gene therapies gain traction, they are expected to significantly expand the market, offering an innovative, cost-effective, and long-term solution for hemophilia patients globally. With this shift, the hemophilia market trends are set to align with the growing demand for advanced, sustainable treatment options.

Convenience and Personalization in Hemophilia Treatments

As the global hemophilia market continues to grow, there is an increasing emphasis on treatments that offer greater convenience and personalization. Many current therapies, particularly intravenous infusions, are time-consuming, require frequent hospital visits, and can be inconvenient for patients. As patient-centric care becomes more important, the demand for therapies that improve quality of life through ease of administration and personalized treatment regimens is on the rise. This has spurred the development of more accessible and patient-friendly treatment options, further driving innovation in the hemophilia market. For instance, in January 2025, the FDA approved Concizumab-mtci (Alhemo), the first subcutaneous prophylactic treatment for Hemophilia A and B with inhibitors. This novel treatment, based on phase 3 clinical trial data, offers patients a more convenient option by providing a subcutaneous injection, eliminating the need for intravenous infusions. The approval of Alhemo is a game-changer for patients with inhibitors, providing a much-needed alternative to existing treatments and increasing the flexibility and convenience of managing hemophilia. With this new approval, the hemophilia market is witnessing a shift toward therapies that are not only more effective but also tailored to the individual needs of patients, making treatment more accessible. As a result, this market is expanding rapidly, with greater opportunities for personalized care solutions to address the diverse needs of hemophilia patients worldwide.

Hemophilia Industry Segmentation:

Analysis by Type:

  • Hemophilia A
  • Hemophilia B
  • Hemophilia C
  • Others

As per the hemophilia market outlook, in 2024, the hemophilia A segment led the market, accounting for 75.3% of the total market share driven by higher prevalence of Hemophilia A compared to Hemophilia B, with more patients diagnosed with Factor VIII deficiency. Additionally, advancements in therapies specifically targeting Hemophilia A, such as gene therapy and improved clotting factor products, have contributed to this growth. The increasing diagnosis rate and the popularity of prophylactic treatments that prevent bleeding episodes have also played a critical role in driving the demand for Hemophilia A treatments. With the continued focus on developing more effective, long-lasting therapies, the Hemophilia A segment is expected to maintain its leading position in the global market.

Analysis by Treatment:

  • On-Demand
  • Prophylaxis

In 2024, the on-demand segment led the hemophilia market, driven by the preference for immediate intervention to manage bleeding episodes. On-demand therapy is primarily used to treat spontaneous bleeds and trauma, offering patients quick access to treatment when needed. This segment has gained traction due to its flexible and responsive nature, particularly for patients who experience occasional bleeding episodes. Additionally, the development of more advanced and easier-to-administer on-demand treatments, such as subcutaneous injections and extended-acting factor therapies, has enhanced patient compliance and convenience. As these therapies continue to improve in terms of effectiveness and ease of use, the on-demand treatment segment remains a crucial player in the Hemophilia market.

Analysis by Therapy:

  • Replacement Therapy
  • ITI Therapy
  • Gene Therapy

In 2024, the replacement therapy segment led the hemophilia market, accounting for 61.7% of the total market share, driven by the effectiveness of replacement therapies in treating both Hemophilia A and B. These therapies involve replacing the missing clotting factors (Factor VIII for Hemophilia A and Factor IX for Hemophilia B), directly addressing the root cause of bleeding episodes. With continuous advancements in the half-life of clotting factors, extended-acting therapies have gained preference, providing longer protection against bleeding episodes and reducing the frequency of infusions. The widespread use of prophylactic replacement therapy has also contributed to the segment's leading position, as it helps patients maintain better overall health and quality of life.

Regional Analysis:

  • North America
    • United States
    • Canada
  • Asia Pacific
    • China
    • Japan
    • India
    • South Korea
    • Australia
    • Indonesia
    • Others
  • Europe
    • Germany
    • France
    • United Kingdom
    • Italy
    • Spain
    • Russia
    • Others
  • Latin America
    • Brazil
    • Mexico
    • Others
  • Middle East and Africa

In 2024, the North America segment led the hemophilia market, accounting for 49.7% of the total market share, driven by its high healthcare expenditure, advanced healthcare infrastructure, and extensive access to innovative therapies. North America also benefits from a well-established network of specialized hemophilia treatment centers (HTCs) and significant government support for healthcare research and development. Furthermore, the presence of leading pharmaceutical companies developing innovative hemophilia treatments has contributed to the rapid adoption of novel therapies. The increased diagnosis rates, patient awareness, and access to newer treatments like gene therapy and extended-acting clotting factors have significantly boosted the demand for hemophilia care in North America, solidifying its position as the largest market.

Key Regional Takeaways:

United States Hemophilia Market Analysis

In 2024, the United States accounted for 93.50% of the hemophilia market in North America, driven by multiple factors. United States is a significant contributor to this market share owing to the increase in specialized hemophilia treatment centers (HTCs) across the country. As per the National Bleeding Disorders Foundation, approximately 141 federally funded treatment centers and programs are active in the US. These centers are integral in delivering comprehensive care, improving early diagnosis, and enhancing patient outcomes. The rise in public and private sector funding has led to the expansion of HTCs, ensuring more widespread access to advanced treatments. With continued investments in healthcare infrastructure and specialized care models, adoption rates of hemophilia therapies are steadily increasing. The growing presence of HTCs, combined with strategic collaborations between healthcare providers and pharmaceutical companies, strengthens the market by offering patients more reliable diagnosis and treatment options. This development continues to foster greater patient engagement and boosts the overall growth of the market.

Asia Pacific Hemophilia Market Analysis

The Asia-Pacific region is experiencing a notable rise in hemophilia adoption, largely driven by the increasing prevalence of genetic disorders in the area. According to the Tata Institute for Genetics and Society, there are 5000-8000 rare genetic diseases identified globally, with 450 cases reported in India. Hemophilia, particularly its genetic transmission through inherited X-linked recessive mutations, plays a significant role in the increasing patient population. Public health initiatives focusing on early detection, genetic counseling, and awareness campaigns have improved the identification of hemophilia patients. Advances in diagnostic technologies further contribute to the quicker identification of genetic markers related to the disease. Additionally, better healthcare frameworks and government support are promoting the management of hemophilia across the region. These factors combined with the growing attention to rare genetic conditions create a positive environment for expanding hemophilia care and interventions in Asia-Pacific.

Europe Hemophilia Market Analysis

Europe's aging population is influencing the growing demand for specialized hemophilia care, as more individuals are living longer with the condition. By the beginning of 2024, Europe's population was estimated at 449.3 Million, with over 20% aged 65 or older. As life expectancy rises, patients diagnosed with hemophilia in their early years continue to require lifelong treatment, leading to an increased demand for healthcare resources. This demographic shift is placing greater focus on managing age-related complications in hemophilia, such as joint damage and associated comorbidities. Healthcare systems are adapting to this change by refining long-term therapy plans and mobility support services. The rise in geriatric patients with hemophilia is prompting healthcare providers to tailor treatment approaches to meet the needs of elderly patients, ensuring consistent access to replacement therapies and rehabilitation, driving the demand for specialized services in the region.

Latin America Hemophilia Market Analysis

In Latin America, the adoption of hemophilia treatments is on the rise due to the growing number of diagnosed cases in the region. Government data from Colombia in 2021 reported a prevalence of hemophilia A of 4.29 cases per 100,000 people. The increasing number of diagnoses, along with better access to healthcare services, is helping to raise awareness of the disease burden. Population screening programs have been instrumental in identifying more individuals affected by hemophilia, which in turn has heightened the demand for consistent and comprehensive treatment plans. As more patients are diagnosed and healthcare access improves, the need for ongoing therapy and specialized care is driving the market's expansion in Latin America.

Middle East and Africa Hemophilia Market Analysis

In the Middle East and Africa, hemophilia treatment adoption is rising as regional healthcare infrastructure continues to expand. The prevalence of hemophilia in countries across the Middle East and North Africa (MENA) region-such as Iraq, Iran, Turkey, Egypt, Jordan, Syria, and Saudi Arabia-ranges from 1.4 to 8.1 per 100,000 people. Strengthening healthcare systems and the introduction of new therapy and diagnostic centers are improving access to specialized services and early detection. Advances in diagnostic capabilities and treatment options have contributed to greater hemophilia care availability in underserved regions. As healthcare infrastructure continues to improve, more patients are gaining access to effective treatments, resulting in increased adoption of hemophilia care across the Middle East and Africa.

Competitive Landscape:

As per the hemophilia market forecast, leading companies in the market are focusing on R&D to develop advanced formulations with better efficacy and fewer side effects, reflecting the shift toward safer and more effective treatments. Expansions through acquisitions, partnerships, and global collaborations are driving the market, enabling companies to access new markets and technologies. Regulatory compliance and sustainable manufacturing remain key priorities, underscoring their commitment to quality, safety, and environmental responsibility.

The report provides a comprehensive analysis of the competitive landscape in the hemophilia market with detailed profiles of all major companies, including:

  • Baxter International Inc.
  • Bayer AG
  • BioMarin Pharmaceutical Inc.
  • CSL Behring (CSL Limited)
  • F. Hoffmann-La Roche AG
  • Grifols S.A.
  • Kedrion S.p.A.
  • Novo Nordisk A/S
  • Octapharma AG
  • Pfizer Inc.
  • Sanofi S.A.
  • Takeda Pharmaceutical Company Limited

Key Questions Answered in This Report

  • 1.How big is the hemophilia market?
  • 2.What is the future outlook of hemophilia market?
  • 3.What are the key factors driving the hemophilia market?
  • 4.Which region accounts for the largest hemophilia market share?
  • 5.Which are the leading companies in the global hemophilia market?

Table of Contents

1 Preface

2 Scope and Methodology

  • 2.1 Objectives of the Study
  • 2.2 Stakeholders
  • 2.3 Data Sources
    • 2.3.1 Primary Sources
    • 2.3.2 Secondary Sources
  • 2.4 Market Estimation
    • 2.4.1 Bottom-Up Approach
    • 2.4.2 Top-Down Approach
  • 2.5 Forecasting Methodology

3 Executive Summary

4 Introduction

  • 4.1 Overview
  • 4.2 Key Industry Trends

5 Global Hemophilia Market

  • 5.1 Market Overview
  • 5.2 Market Performance
  • 5.3 Impact of COVID-19
  • 5.4 Market Forecast

6 Market Breakup by Type

  • 6.1 Hemophilia A
    • 6.1.1 Market Trends
    • 6.1.2 Market Forecast
  • 6.2 Hemophilia B
    • 6.2.1 Market Trends
    • 6.2.2 Market Forecast
  • 6.3 Hemophilia C
    • 6.3.1 Market Trends
    • 6.3.2 Market Forecast
  • 6.4 Others
    • 6.4.1 Market Trends
    • 6.4.2 Market Forecast

7 Market Breakup by Treatment

  • 7.1 On-Demand
    • 7.1.1 Market Trends
    • 7.1.2 Market Forecast
  • 7.2 Prophylaxis
    • 7.2.1 Market Trends
    • 7.2.2 Market Forecast

8 Market Breakup by Therapy

  • 8.1 Replacement Therapy
    • 8.1.1 Market Trends
    • 8.1.2 Market Forecast
  • 8.2 ITI Therapy
    • 8.2.1 Market Trends
    • 8.2.2 Market Forecast
  • 8.3 Gene Therapy
    • 8.3.1 Market Trends
    • 8.3.2 Market Forecast

9 Market Breakup by Region

  • 9.1 North America
    • 9.1.1 United States
      • 9.1.1.1 Market Trends
      • 9.1.1.2 Market Forecast
    • 9.1.2 Canada
      • 9.1.2.1 Market Trends
      • 9.1.2.2 Market Forecast
  • 9.2 Asia-Pacific
    • 9.2.1 China
      • 9.2.1.1 Market Trends
      • 9.2.1.2 Market Forecast
    • 9.2.2 Japan
      • 9.2.2.1 Market Trends
      • 9.2.2.2 Market Forecast
    • 9.2.3 India
      • 9.2.3.1 Market Trends
      • 9.2.3.2 Market Forecast
    • 9.2.4 South Korea
      • 9.2.4.1 Market Trends
      • 9.2.4.2 Market Forecast
    • 9.2.5 Australia
      • 9.2.5.1 Market Trends
      • 9.2.5.2 Market Forecast
    • 9.2.6 Indonesia
      • 9.2.6.1 Market Trends
      • 9.2.6.2 Market Forecast
    • 9.2.7 Others
      • 9.2.7.1 Market Trends
      • 9.2.7.2 Market Forecast
  • 9.3 Europe
    • 9.3.1 Germany
      • 9.3.1.1 Market Trends
      • 9.3.1.2 Market Forecast
    • 9.3.2 France
      • 9.3.2.1 Market Trends
      • 9.3.2.2 Market Forecast
    • 9.3.3 United Kingdom
      • 9.3.3.1 Market Trends
      • 9.3.3.2 Market Forecast
    • 9.3.4 Italy
      • 9.3.4.1 Market Trends
      • 9.3.4.2 Market Forecast
    • 9.3.5 Spain
      • 9.3.5.1 Market Trends
      • 9.3.5.2 Market Forecast
    • 9.3.6 Russia
      • 9.3.6.1 Market Trends
      • 9.3.6.2 Market Forecast
    • 9.3.7 Others
      • 9.3.7.1 Market Trends
      • 9.3.7.2 Market Forecast
  • 9.4 Latin America
    • 9.4.1 Brazil
      • 9.4.1.1 Market Trends
      • 9.4.1.2 Market Forecast
    • 9.4.2 Mexico
      • 9.4.2.1 Market Trends
      • 9.4.2.2 Market Forecast
    • 9.4.3 Others
      • 9.4.3.1 Market Trends
      • 9.4.3.2 Market Forecast
  • 9.5 Middle East and Africa
    • 9.5.1 Market Trends
    • 9.5.2 Market Breakup by Country
    • 9.5.3 Market Forecast

10 SWOT Analysis

  • 10.1 Overview
  • 10.2 Strengths
  • 10.3 Weaknesses
  • 10.4 Opportunities
  • 10.5 Threats

11 Value Chain Analysis

12 Porters Five Forces Analysis

  • 12.1 Overview
  • 12.2 Bargaining Power of Buyers
  • 12.3 Bargaining Power of Suppliers
  • 12.4 Degree of Competition
  • 12.5 Threat of New Entrants
  • 12.6 Threat of Substitutes

13 Price Analysis

14 Competitive Landscape

  • 14.1 Market Structure
  • 14.2 Key Players
  • 14.3 Profiles of Key Players
    • 14.3.1 Baxter International Inc.
      • 14.3.1.1 Company Overview
      • 14.3.1.2 Product Portfolio
      • 14.3.1.3 Financials
      • 14.3.1.4 SWOT Analysis
    • 14.3.2 Bayer AG
      • 14.3.2.1 Company Overview
      • 14.3.2.2 Product Portfolio
      • 14.3.2.3 Financials
      • 14.3.2.4 SWOT Analysis
    • 14.3.3 BioMarin Pharmaceutical Inc.
      • 14.3.3.1 Company Overview
      • 14.3.3.2 Product Portfolio
      • 14.3.3.3 Financials
      • 14.3.3.4 SWOT Analysis
    • 14.3.4 CSL Behring (CSL Limited)
      • 14.3.4.1 Company Overview
      • 14.3.4.2 Product Portfolio
    • 14.3.5 F. Hoffmann-La Roche AG
      • 14.3.5.1 Company Overview
      • 14.3.5.2 Product Portfolio
      • 14.3.5.3 Financials
    • 14.3.6 Grifols S.A.
      • 14.3.6.1 Company Overview
      • 14.3.6.2 Product Portfolio
      • 14.3.6.3 Financials
      • 14.3.6.4 SWOT Analysis
    • 14.3.7 Kedrion S.p.A.
      • 14.3.7.1 Company Overview
      • 14.3.7.2 Product Portfolio
    • 14.3.8 Novo Nordisk A/S
      • 14.3.8.1 Company Overview
      • 14.3.8.2 Product Portfolio
      • 14.3.8.3 Financials
      • 14.3.8.4 SWOT Analysis
    • 14.3.9 Octapharma AG
      • 14.3.9.1 Company Overview
      • 14.3.9.2 Product Portfolio
      • 14.3.9.3 SWOT Analysis
    • 14.3.10 Pfizer Inc.
      • 14.3.10.1 Company Overview
      • 14.3.10.2 Product Portfolio
      • 14.3.10.3 Financials
      • 14.3.10.4 SWOT Analysis
    • 14.3.11 Sanofi S.A.
      • 14.3.11.1 Company Overview
      • 14.3.11.2 Product Portfolio
      • 14.3.11.3 Financials
      • 14.3.11.4 SWOT Analysis
    • 14.3.12 Takeda Pharmaceutical Company Limited
      • 14.3.12.1 Company Overview
      • 14.3.12.2 Product Portfolio
      • 14.3.12.3 Financials
      • 14.3.12.4 SWOT Analysis

List of Figures

  • Figure 1: Global: Hemophilia Market: Major Drivers and Challenges
  • Figure 2: Global: Hemophilia Market: Sales Value (in Billion USD), 2019-2024
  • Figure 3: Global: Hemophilia Market Forecast: Sales Value (in Billion USD), 2025-2033
  • Figure 4: Global: Hemophilia Market: Breakup by Type (in %), 2024
  • Figure 5: Global: Hemophilia Market: Breakup by Treatment (in %), 2024
  • Figure 6: Global: Hemophilia Market: Breakup by Therapy (in %), 2024
  • Figure 7: Global: Hemophilia Market: Breakup by Region (in %), 2024
  • Figure 8: Global: Hemophilia (Hemophilia A) Market: Sales Value (in Million USD), 2019 & 2024
  • Figure 9: Global: Hemophilia (Hemophilia A) Market Forecast: Sales Value (in Million USD), 2025-2033
  • Figure 10: Global: Hemophilia (Hemophilia B) Market: Sales Value (in Million USD), 2019 & 2024
  • Figure 11: Global: Hemophilia (Hemophilia B) Market Forecast: Sales Value (in Million USD), 2025-2033
  • Figure 12: Global: Hemophilia (Hemophilia C) Market: Sales Value (in Million USD), 2019 & 2024
  • Figure 13: Global: Hemophilia (Hemophilia C) Market Forecast: Sales Value (in Million USD), 2025-2033
  • Figure 14: Global: Hemophilia (Other Types) Market: Sales Value (in Million USD), 2019 & 2024
  • Figure 15: Global: Hemophilia (Other Types) Market Forecast: Sales Value (in Million USD), 2025-2033
  • Figure 16: Global: Hemophilia (On-Demand) Market: Sales Value (in Million USD), 2019 & 2024
  • Figure 17: Global: Hemophilia (On-Demand) Market Forecast: Sales Value (in Million USD), 2025-2033
  • Figure 18: Global: Hemophilia (Prophylaxis) Market: Sales Value (in Million USD), 2019 & 2024
  • Figure 19: Global: Hemophilia (Prophylaxis) Market Forecast: Sales Value (in Million USD), 2025-2033
  • Figure 20: Global: Hemophilia (Replacement Therapy) Market: Sales Value (in Million USD), 2019 & 2024
  • Figure 21: Global: Hemophilia (Replacement Therapy) Market Forecast: Sales Value (in Million USD), 2025-2033
  • Figure 22: Global: Hemophilia (ITI Therapy) Market: Sales Value (in Million USD), 2019 & 2024
  • Figure 23: Global: Hemophilia (ITI Therapy) Market Forecast: Sales Value (in Million USD), 2025-2033
  • Figure 24: Global: Hemophilia (Gene Therapy) Market: Sales Value (in Million USD), 2019 & 2024
  • Figure 25: Global: Hemophilia (Gene Therapy) Market Forecast: Sales Value (in Million USD), 2025-2033
  • Figure 26: North America: Hemophilia Market: Sales Value (in Million USD), 2019 & 2024
  • Figure 27: North America: Hemophilia Market Forecast: Sales Value (in Million USD), 2025-2033
  • Figure 28: United States: Hemophilia Market: Sales Value (in Million USD), 2019 & 2024
  • Figure 29: United States: Hemophilia Market Forecast: Sales Value (in Million USD), 2025-2033
  • Figure 30: Canada: Hemophilia Market: Sales Value (in Million USD), 2019 & 2024
  • Figure 31: Canada: Hemophilia Market Forecast: Sales Value (in Million USD), 2025-2033
  • Figure 32: Asia-Pacific: Hemophilia Market: Sales Value (in Million USD), 2019 & 2024
  • Figure 33: Asia-Pacific: Hemophilia Market Forecast: Sales Value (in Million USD), 2025-2033
  • Figure 34: China: Hemophilia Market: Sales Value (in Million USD), 2019 & 2024
  • Figure 35: China: Hemophilia Market Forecast: Sales Value (in Million USD), 2025-2033
  • Figure 36: Japan: Hemophilia Market: Sales Value (in Million USD), 2019 & 2024
  • Figure 37: Japan: Hemophilia Market Forecast: Sales Value (in Million USD), 2025-2033
  • Figure 38: India: Hemophilia Market: Sales Value (in Million USD), 2019 & 2024
  • Figure 39: India: Hemophilia Market Forecast: Sales Value (in Million USD), 2025-2033
  • Figure 40: South Korea: Hemophilia Market: Sales Value (in Million USD), 2019 & 2024
  • Figure 41: South Korea: Hemophilia Market Forecast: Sales Value (in Million USD), 2025-2033
  • Figure 42: Australia: Hemophilia Market: Sales Value (in Million USD), 2019 & 2024
  • Figure 43: Australia: Hemophilia Market Forecast: Sales Value (in Million USD), 2025-2033
  • Figure 44: Indonesia: Hemophilia Market: Sales Value (in Million USD), 2019 & 2024
  • Figure 45: Indonesia: Hemophilia Market Forecast: Sales Value (in Million USD), 2025-2033
  • Figure 46: Others: Hemophilia Market: Sales Value (in Million USD), 2019 & 2024
  • Figure 47: Others: Hemophilia Market Forecast: Sales Value (in Million USD), 2025-2033
  • Figure 48: Europe: Hemophilia Market: Sales Value (in Million USD), 2019 & 2024
  • Figure 49: Europe: Hemophilia Market Forecast: Sales Value (in Million USD), 2025-2033
  • Figure 50: Germany: Hemophilia Market: Sales Value (in Million USD), 2019 & 2024
  • Figure 51: Germany: Hemophilia Market Forecast: Sales Value (in Million USD), 2025-2033
  • Figure 52: France: Hemophilia Market: Sales Value (in Million USD), 2019 & 2024
  • Figure 53: France: Hemophilia Market Forecast: Sales Value (in Million USD), 2025-2033
  • Figure 54: United Kingdom: Hemophilia Market: Sales Value (in Million USD), 2019 & 2024
  • Figure 55: United Kingdom: Hemophilia Market Forecast: Sales Value (in Million USD), 2025-2033
  • Figure 56: Italy: Hemophilia Market: Sales Value (in Million USD), 2019 & 2024
  • Figure 57: Italy: Hemophilia Market Forecast: Sales Value (in Million USD), 2025-2033
  • Figure 58: Spain: Hemophilia Market: Sales Value (in Million USD), 2019 & 2024
  • Figure 59: Spain: Hemophilia Market Forecast: Sales Value (in Million USD), 2025-2033
  • Figure 60: Russia: Hemophilia Market: Sales Value (in Million USD), 2019 & 2024
  • Figure 61: Russia: Hemophilia Market Forecast: Sales Value (in Million USD), 2025-2033
  • Figure 62: Others: Hemophilia Market: Sales Value (in Million USD), 2019 & 2024
  • Figure 63: Others: Hemophilia Market Forecast: Sales Value (in Million USD), 2025-2033
  • Figure 64: Latin America: Hemophilia Market: Sales Value (in Million USD), 2019 & 2024
  • Figure 65: Latin America: Hemophilia Market Forecast: Sales Value (in Million USD), 2025-2033
  • Figure 66: Brazil: Hemophilia Market: Sales Value (in Million USD), 2019 & 2024
  • Figure 67: Brazil: Hemophilia Market Forecast: Sales Value (in Million USD), 2025-2033
  • Figure 68: Mexico: Hemophilia Market: Sales Value (in Million USD), 2019 & 2024
  • Figure 69: Mexico: Hemophilia Market Forecast: Sales Value (in Million USD), 2025-2033
  • Figure 70: Others: Hemophilia Market: Sales Value (in Million USD), 2019 & 2024
  • Figure 71: Others: Hemophilia Market Forecast: Sales Value (in Million USD), 2025-2033
  • Figure 72: Middle East and Africa: Hemophilia Market: Sales Value (in Million USD), 2019 & 2024
  • Figure 73: Middle East and Africa: Hemophilia Market: Breakup by Country (in %), 2024
  • Figure 74: Middle East and Africa: Hemophilia Market Forecast: Sales Value (in Million USD), 2025-2033
  • Figure 75: Global: Hemophilia Industry: SWOT Analysis
  • Figure 76: Global: Hemophilia Industry: Value Chain Analysis
  • Figure 77: Global: Hemophilia Industry: Porter's Five Forces Analysis

List of Tables

  • Table 1: Global: Hemophilia Market: Key Industry Highlights, 2024 and 2033
  • Table 2: Global: Hemophilia Market Forecast: Breakup by Type (in Million USD), 2025-2033
  • Table 3: Global: Hemophilia Market Forecast: Breakup by Treatment (in Million USD), 2025-2033
  • Table 4: Global: Hemophilia Market Forecast: Breakup by Therapy (in Million USD), 2025-2033
  • Table 5: Global: Hemophilia Market Forecast: Breakup by Region (in Million USD), 2025-2033
  • Table 6: Global: Hemophilia Market: Competitive Structure
  • Table 7: Global: Hemophilia Market: Key Players